Upload Avatar (500 x 500)
杨沛然
Basic Medical Sciences
北京协和医学院
北京
Language: 英语, 中文
肺动脉高压
尘肺病
慢性阻塞性肺病
分子机制
病理生理学
干预策略
新靶点
临床前实验
转化研究
多学科合作
Areas of Focus
- 肺血管病和呼吸系统疾病研究
Work Experience
- 2021-至今 - 中国医学科学院基础医学研究所&北京协和医学院基础学院 - 课题组长, 博士研究生导师
Academic Background & Achievements
- 2008-2017 学士、硕士、博士学位: 英国剑桥大学
- 2017-2020 博士后: 美国哈佛大学医学院
- 2021- 引进人才: 中国医学科学院基础医学研究所&北京协和医学院基础学院
Publications
- Sotatercept for Pulmonary Arterial Hypertension. (Letter to Editor), Yang P, Bocobo GA, Yu PB, 2021
- The role of bone morphogenetic protein signaling in vascular calcification. (Review), Yang P, Troncone L, Augur ZM, Kim SSJ, McNeil ME, Yu PB, 2020
- ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension., Yung LM, Yang P, Joshi S, Augur ZM, Kim SSJ, Bocobo GA, Dinter T, Troncone L, Chen PS, McNeil ME, Southwood M, Poli de Frias S, Knopf J, Rosas IO, Sako D, Pearsall RS, Quisel JD, Li G, Kumar R, Yu PB, 2020
- A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension., Yang P, Read C, Kuc RE, Nyimanu D, Williams TL, Crosby A, Buonincontri G, Southwood M, Sawiak SJ, Morrell NW, Davenport AP, Maguire JJ, 2019
- Elabela/Toddler Is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension., Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP, 2017
- [Pyr1]Apelin(1-12) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr1]Apelin-13., Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC, Cheriyan J, Wilkinson IB, Davenport AP, Maguire JJ, 2017
- Cardiac action of the first G protein biased small molecule apelin agonist., Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP, 2016
- Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. (Review), Yang P, Maguire JJ, Davenport AP, 2015
